Gregory Poland, MD, MATh, FIDSA, MACP, FRCP (London)

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Merck
    Topic:
    Experimental pneumococcal vaccines
    Date added:
    03/10/2026
    Date updated:
    03/10/2026
    Relationship end date:
    03/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Syneos
    Topic:
    Experimental vaccines
    Date added:
    03/10/2026
    Date updated:
    03/10/2026
    Relationship end date:
    02/02/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Orexo
    Topic:
    Vaccine adjuvant platform
    Date added:
    03/10/2026
    Date updated:
    03/10/2026
    Relationship end date:
    03/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    AziTech
    Topic:
    Remote diagnostics
    Date added:
    03/10/2026
    Date updated:
    03/10/2026
    Relationship end date:
    03/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Bavarian Nordic
    Topic:
    Chik vaccines
    Date added:
    03/10/2026
    Date updated:
    03/10/2026
    Relationship end date:
    03/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    GSK
    Topic:
    SHingles Education
    Date added:
    03/10/2026
    Date updated:
    03/10/2026
    Relationship end date:
    03/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Advisor
    Ineligible company:
    Moderna
    Topic:
    DIrected fellowship program
    Date added:
    03/10/2026
    Date updated:
    03/10/2026
    Relationship end date:
    03/03/2025
Return to FAAIS 2026 Annual Meeting